CN105380830A - Composition capable of removing pockmarks and inhibiting acne generation, and application thereof - Google Patents
Composition capable of removing pockmarks and inhibiting acne generation, and application thereof Download PDFInfo
- Publication number
- CN105380830A CN105380830A CN201510873881.2A CN201510873881A CN105380830A CN 105380830 A CN105380830 A CN 105380830A CN 201510873881 A CN201510873881 A CN 201510873881A CN 105380830 A CN105380830 A CN 105380830A
- Authority
- CN
- China
- Prior art keywords
- component
- acne
- parts
- phase component
- trace
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010000496 acne Diseases 0.000 title claims abstract description 83
- 208000002874 Acne Vulgaris Diseases 0.000 title claims abstract description 77
- 239000000203 mixture Substances 0.000 title claims abstract description 44
- 230000002401 inhibitory effect Effects 0.000 title abstract description 6
- VGEREEWJJVICBM-UHFFFAOYSA-N phloretin Chemical compound C1=CC(O)=CC=C1CCC(=O)C1=C(O)C=C(O)C=C1O VGEREEWJJVICBM-UHFFFAOYSA-N 0.000 claims abstract description 67
- -1 acetyl chitosamine Chemical compound 0.000 claims abstract description 41
- ZWTDXYUDJYDHJR-UHFFFAOYSA-N (E)-1-(2,4-dihydroxyphenyl)-3-(2,4-dihydroxyphenyl)-2-propen-1-one Natural products OC1=CC(O)=CC=C1C=CC(=O)C1=CC=C(O)C=C1O ZWTDXYUDJYDHJR-UHFFFAOYSA-N 0.000 claims abstract description 33
- YQHMWTPYORBCMF-UHFFFAOYSA-N Naringenin chalcone Natural products C1=CC(O)=CC=C1C=CC(=O)C1=C(O)C=C(O)C=C1O YQHMWTPYORBCMF-UHFFFAOYSA-N 0.000 claims abstract description 33
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 claims abstract description 29
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 claims abstract description 28
- WYQVAPGDARQUBT-FGWHUCSPSA-N Madecassol Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(CC[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O WYQVAPGDARQUBT-FGWHUCSPSA-N 0.000 claims abstract description 26
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 claims abstract description 26
- WYQVAPGDARQUBT-XCWYDTOWSA-N asiaticoside Natural products O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2 WYQVAPGDARQUBT-XCWYDTOWSA-N 0.000 claims abstract description 26
- 229940022757 asiaticoside Drugs 0.000 claims abstract description 26
- QCYLIQBVLZBPNK-UHFFFAOYSA-N asiaticoside A Natural products O1C(C(=O)C(C)C)=CC(C)C(C2(C(OC(C)=O)CC34C5)C)C1CC2(C)C3CCC(C1(C)C)C45CCC1OC1OCC(O)C(O)C1O QCYLIQBVLZBPNK-UHFFFAOYSA-N 0.000 claims abstract description 26
- 239000002994 raw material Substances 0.000 claims abstract description 26
- 229920000669 heparin Polymers 0.000 claims abstract description 23
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 claims abstract description 21
- 229940036350 bisabolol Drugs 0.000 claims abstract description 21
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 claims abstract description 21
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 claims abstract description 20
- 229960001008 heparin sodium Drugs 0.000 claims abstract description 20
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 claims abstract description 20
- 229960003232 troxerutin Drugs 0.000 claims abstract description 19
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims abstract description 10
- 230000003255 anti-acne Effects 0.000 claims description 59
- 230000012010 growth Effects 0.000 claims description 48
- 230000001629 suppression Effects 0.000 claims description 40
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 39
- 239000003921 oil Substances 0.000 claims description 38
- 229960003720 enoxolone Drugs 0.000 claims description 31
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 claims description 30
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 claims description 30
- 235000002378 plant sterols Nutrition 0.000 claims description 28
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 24
- 229920001661 Chitosan Polymers 0.000 claims description 17
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims description 17
- 239000000686 essence Substances 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 13
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 13
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 13
- 229960005323 phenoxyethanol Drugs 0.000 claims description 13
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 12
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 12
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 12
- 229960000458 allantoin Drugs 0.000 claims description 12
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims description 12
- 239000008367 deionised water Substances 0.000 claims description 12
- 229910021641 deionized water Inorganic materials 0.000 claims description 12
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 12
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 12
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 claims description 12
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 claims description 12
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 12
- 229940042585 tocopherol acetate Drugs 0.000 claims description 12
- SMITZRKODWNNBA-UHFFFAOYSA-N hexadecyl dihydrogen phosphate;potassium Chemical compound [K].CCCCCCCCCCCCCCCCOP(O)(O)=O SMITZRKODWNNBA-UHFFFAOYSA-N 0.000 claims description 11
- 239000010495 camellia oil Substances 0.000 claims description 10
- 239000000230 xanthan gum Substances 0.000 claims description 9
- 229920001285 xanthan gum Polymers 0.000 claims description 9
- 235000010493 xanthan gum Nutrition 0.000 claims description 9
- 229940082509 xanthan gum Drugs 0.000 claims description 9
- 239000006071 cream Substances 0.000 claims description 8
- 239000000839 emulsion Substances 0.000 claims description 8
- 230000001815 facial effect Effects 0.000 claims description 7
- 239000000499 gel Substances 0.000 claims description 7
- 229930182478 glucoside Natural products 0.000 claims description 7
- 150000008131 glucosides Chemical class 0.000 claims description 7
- 239000004094 surface-active agent Substances 0.000 claims description 7
- 229940081733 cetearyl alcohol Drugs 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 230000000474 nursing effect Effects 0.000 claims description 4
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 3
- 229940071826 hydroxyethyl cellulose Drugs 0.000 claims description 3
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 3
- 239000002537 cosmetic Substances 0.000 abstract description 11
- 230000009471 action Effects 0.000 abstract description 3
- 206010039580 Scar Diseases 0.000 abstract 1
- 238000005562 fading Methods 0.000 abstract 1
- 239000000419 plant extract Substances 0.000 abstract 1
- 230000006870 function Effects 0.000 description 44
- 239000012071 phase Substances 0.000 description 40
- 230000000694 effects Effects 0.000 description 27
- 210000003491 skin Anatomy 0.000 description 27
- 235000019198 oils Nutrition 0.000 description 26
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 24
- 238000000034 method Methods 0.000 description 15
- 230000003110 anti-inflammatory effect Effects 0.000 description 14
- 238000011156 evaluation Methods 0.000 description 14
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 13
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 13
- 229960004705 kojic acid Drugs 0.000 description 13
- 206010061218 Inflammation Diseases 0.000 description 12
- 229960000271 arbutin Drugs 0.000 description 12
- 230000004054 inflammatory process Effects 0.000 description 12
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 12
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 208000027418 Wounds and injury Diseases 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 210000000274 microglia Anatomy 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 206010052428 Wound Diseases 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 231100000241 scar Toxicity 0.000 description 6
- 230000009897 systematic effect Effects 0.000 description 6
- 239000001500 (2R)-6-methyl-2-[(1R)-4-methyl-1-cyclohex-3-enyl]hept-5-en-2-ol Substances 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 102000003425 Tyrosinase Human genes 0.000 description 5
- 108060008724 Tyrosinase Proteins 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 206010020880 Hypertrophy Diseases 0.000 description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000013521 mastic Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 description 4
- 239000008158 vegetable oil Substances 0.000 description 4
- 206010015150 Erythema Diseases 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000003064 anti-oxidating effect Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 238000004508 fractional distillation Methods 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 210000001732 sebaceous gland Anatomy 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- JZFSMVXQUWRSIW-BTJIZOSBSA-N 11-Deoxoglycyrrhetinic acid Chemical compound C([C@H]1C2=CC[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C JZFSMVXQUWRSIW-BTJIZOSBSA-N 0.000 description 2
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 2
- 241000186427 Cutibacterium acnes Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 2
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000000767 anti-ulcer Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000012496 blank sample Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 238000001631 haemodialysis Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000000322 hemodialysis Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 150000002617 leukotrienes Chemical class 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 229950006780 n-acetylglucosamine Drugs 0.000 description 2
- 235000014593 oils and fats Nutrition 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000003961 penetration enhancing agent Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 229940055019 propionibacterium acne Drugs 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 2
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 2
- 235000005493 rutin Nutrition 0.000 description 2
- 229960004555 rutoside Drugs 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000002374 sebum Anatomy 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 description 1
- 229940100555 2-methyl-4-isothiazolin-3-one Drugs 0.000 description 1
- IOYNGCZNYGEZRO-UHFFFAOYSA-N 3-ethyl-n,n,2-trimethyl-1h-indol-5-amine Chemical compound C1=C(N(C)C)C=C2C(CC)=C(C)NC2=C1 IOYNGCZNYGEZRO-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 1
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 241001147468 Chondrus ocellatus Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 208000036828 Device occlusion Diseases 0.000 description 1
- 241000371997 Eriocheir sinensis Species 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 230000010337 G2 phase Effects 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010025252 Kassinin Proteins 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 206010023330 Keloid scar Diseases 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029098 Neoplasm skin Diseases 0.000 description 1
- 206010030012 Occupational dermatitis Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 241000220324 Pyrus Species 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000004847 absorption spectroscopy Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- CKMXBZGNNVIXHC-UHFFFAOYSA-L ammonium magnesium phosphate hexahydrate Chemical compound [NH4+].O.O.O.O.O.O.[Mg+2].[O-]P([O-])([O-])=O CKMXBZGNNVIXHC-UHFFFAOYSA-L 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical class CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 210000000589 cicatrix Anatomy 0.000 description 1
- AQIXAKUUQRKLND-UHFFFAOYSA-N cimetidine Chemical compound N#C/N=C(/NC)NCCSCC=1N=CNC=1C AQIXAKUUQRKLND-UHFFFAOYSA-N 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 210000000736 corneocyte Anatomy 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000007854 depigmenting agent Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- SOROIESOUPGGFO-UHFFFAOYSA-N diazolidinylurea Chemical compound OCNC(=O)N(CO)C1N(CO)C(=O)N(CO)C1=O SOROIESOUPGGFO-UHFFFAOYSA-N 0.000 description 1
- 229960001083 diazolidinylurea Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 150000002342 glycyrrhetinic acids Chemical class 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229960002358 iodine Drugs 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000003055 low molecular weight heparin Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- KRPAJLYSLFNDOA-UHFFFAOYSA-N mephenesin carbamate Chemical compound CC1=CC=CC=C1OCC(O)COC(N)=O KRPAJLYSLFNDOA-UHFFFAOYSA-N 0.000 description 1
- 229950006838 mephenesin carbamate Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- BEGLCMHJXHIJLR-UHFFFAOYSA-N methylisothiazolinone Chemical compound CN1SC=CC1=O BEGLCMHJXHIJLR-UHFFFAOYSA-N 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000010070 molecular adhesion Effects 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- NMHMNPHRMNGLLB-UHFFFAOYSA-N p-hydroxybenzene propanoic acid Natural products OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
- 235000021017 pears Nutrition 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical group 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 201000010106 skin squamous cell carcinoma Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229910052567 struvite Inorganic materials 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/342—Alcohols having more than seven atoms in an unbroken chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/604—Alkylpolyglycosides; Derivatives thereof, e.g. esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/10—General cosmetic use
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Birds (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a composition capable of removing pockmarks and inhibiting acne generation, and application thereof. The composition comprises a component A and a component B. The component A comprises the following raw materials by weight: 0.1 to 1 part of phytosterol, 0.1 to 2 parts of bisabolol and 0.1 to 1 part of octadecanol glycyrrhetinate. The component B comprises the following raw materials by weight: 0.1 to 1 part of phloretin, 0.5 to 5 parts of acetyl chitosamine, 0.05 to 1 part of heparin sodium, 0.1 to 1 part of asiaticoside and 0.1 to 2 parts of troxerutin. A ratio of the component A to the component B is 0.3-3: 0.85-10. The invention has the following characteristics: all the raw materials are included in the List of Approved Raw Materials for Cosmetics of China; the problems of great usage amount, slow action and generation of new acne in a pockmark removal period of pockmark-removing products prepared from crude plant extract are overcome; and the pockmark-removing composition prepared in the invention is capable of eliminating red acne marks, fading black acne marks, restoring acne scars and inhibiting generation of new acne.
Description
Technical field
The present invention relates to cosmetic field, be specifically related to a kind ofly to there is anti-acne trace and suppress cosmetic composition and the application thereof of acne systematic functions.
Background technology
Pockmark is also known as pox scar, and the one reparation reaction that to be body produce tissue injury, when the damage of skin is dark and corium or large-area skin blemish, the epidermis at this position can not regenerate, will by corium fabric cell, the blood vessel of collagen and hypertrophy replaced, and has so just occurred pockmark.Pockmark is that often because do not obtain treatment suitable in time when comedo shows effect, the inflammatory response of Skin Cell causes the destruction to skin histology, causes the generation of cicatrix because infection inflammation or external force extruding formed.Because the kind of comedo is of all kinds, so the form of youth pockmark also has multiple, and comedo outbreak time inflammatory response more serious, skin histology also destroys more severe; The position of inflammation is darker, and skin histology is also deeplyer destroyed, and the pockmark that may stay in the future is also more serious.
Pox print causes vasodilation when being comedo outbreak, after comedo disappears down, blood vessel can't contract down at once, just define some average red erythema (being commonly called as: red seal), and the inflammatory response of Skin Cell causes the destruction to skin histology, pigementation after inflammation can make the place growing red small pox leave black dirty color (being commonly called as: black print), material is thus formed pox print.
Pockmark herein comprises pox scar and pox print.
Pox refers to comedo, is being commonly called as of acne, and the factors such as also known as " skin sore ", " acne ", the generation of acne is main and hypersteatosis, pilosebaceous duct block, bacteriological infection and inflammatory reaction are closely related.After adolescing, in human body, the level of androgen particularly testosterone raises rapidly, promotes that sebaceous gland is grown and produces a large amount of sebum.The dyskeratosis of pilosebaceous duct causes catheter blockage, dyssebacia simultaneously, forms horn plug and micropowder thorn.Multiple-microorganism especially propionibacterium acnes amount reproduction in hair follicle, the lipase decomposition sebum that propionibacterium acnes produces generates free fatty, chemotactic inflammatory cell and medium simultaneously, final induction also exacerbate inflammation reaction.
Summary of the invention
Technical problem to be solved by this invention is to provide a kind ofly to be had anti-acne trace and suppresses the compositions of acne systematic functions, said composition becomes to assign to prepare with the high-purity raw of natural origin, all raw materials of the present invention are all included in China " approved uses cosmetic material catalogue ", have the red pox print of elimination, subtract light black pox print, repair pox scar and suppress effect that new acne generate.
Another technical problem to be solved by this invention is that this kind has anti-acne trace and suppress the application of compositions at skin care applications of acne systematic function.
The technical scheme that the present invention solves the problems of the technologies described above is as follows: a kind of have anti-acne trace and the compositions of suppression acne growth function, comprises component A and B component,
Described component A comprises the raw material of following weight portion: the stearic alcohol ester 0.1 ~ 1 part of plant sterol 0.1 ~ 1 part, bisabolol 0.1 ~ 2 part and enoxolone;
Described B component comprises the raw material of following weight portion: phloretin 0.1 ~ 1 part, acetyl chitosan 0.5 ~ 5 part, heparin sodium 0.05 ~ 1 part, asiaticoside 0.1 ~ 1 part and troxerutin 0.1 ~ 2 part;
Component A and B component weight ratio are 0.3 ~ 3:0.85 ~ 10.
The invention has the beneficial effects as follows: feature of the present invention is that all raw materials are all included in China " approved uses cosmetic material catalogue ", become to assign to prepare with the high-purity raw of natural origin, avoid using Plant crude extract anti-acne trace product consumption be large to prepare, the problem of long new pox again during slow, the anti-acne trace of taking effect, anti-acne trace product prepared by the present invention has to be eliminated red pox print, subtracts light black pox print, repairs pox scar and suppress the function of the generation of new acne.
On the basis of technique scheme, the preferred technical scheme of the present invention is as follows:
Preferably, a kind of have anti-acne trace and the compositions of suppression acne growth function, comprises component A and B component,
Described component A comprises the raw material of following weight portion: the stearic alcohol ester 0.1 ~ 0.5 part of plant sterol 0.2 ~ 1 part, bisabolol 0.1 ~ 1 part and enoxolone;
Described B component comprises the raw material of following weight portion: phloretin 0.1 ~ 1 part, acetyl chitosan 0.5 ~ 4 part, heparin sodium 0.05 ~ 0.5 part, asiaticoside 0.1 ~ 1 part and troxerutin 0.1 ~ 20 part;
Component A and B component weight ratio are 0.4 ~ 2.5:0.85 ~ 8.5.
Preferably, a kind of have anti-acne trace and the compositions of suppression acne growth function, comprises component A and B component,
Described component A comprises the raw material of following weight portion: the stearic alcohol ester 0.5 part of plant sterol 0.5 part, bisabolol 0.5 part and enoxolone;
Described B component comprises the raw material of following weight portion: phloretin 0.5 part, acetyl chitosan 3 parts, heparin sodium 0.5 part, asiaticoside 0.5 part and troxerutin 1.5 parts;
Component A and B component weight ratio are 1.5:6.
Described have anti-acne trace and the application of compositions on skin nursing products of suppression acne growth function.
Preferably, a kind of have anti-acne trace and the cream of suppression acne growth function, and every 100 weight portion cream comprise the molten phase component of following oil and water-dissolving phase component:
The molten phase component of oil: comprise as the component A in claim 1 2.0 parts, also comprise cetearyl glucoside 3 parts, 0.5 part, Phosphoric acid monohexadecyl ester potassium, tea oil 4 parts, cetearyl alcohol 1.8 parts, Vitamin E acetate 0.1 part and polydimethylsiloxane 1 part,
Water-dissolving phase component: comprise as the B component in claim 1 7.0 parts, also comprise disodiumedetate 0.05 part, allantoin 0.2 part, glycerol 6 parts, butanediol 4 parts, sodium polyacrylate 0.3 part, xanthan gum 0.1 part, hyaluronate sodium 0.05 part, phenoxyethanol 0.4 part, methyl hydroxybenzoate 0.2 part and 0.05 part, essence
Surplus is supplied with deionized water.
On the basis of technique scheme, of the present invention have anti-acne trace and suppress the application of compositions on skin nursing products of acne growth function as follows:
Have anti-acne trace and an emulsion for suppression acne growth function, every 100 weight portion emulsions comprise the molten phase component of following oil and water-dissolving phase component:
The molten phase component of oil: comprise as the component A in claim 1 1.5 parts, also comprise cetearyl glucoside 1.5 parts, 0.3 part, Phosphoric acid monohexadecyl ester potassium, tea oil 2 parts, cetearyl alcohol 0.8 part, Vitamin E acetate 0.1 part and polydimethylsiloxane 1 part,
Water-dissolving phase component: comprise as the B component in claim 1 4.0 parts, also comprise disodiumedetate 0.05 part, allantoin 0.2 part, glycerol 6 parts, butanediol 4 parts, sodium polyacrylate 0.2 part, xanthan gum 0.1 part, hyaluronate sodium 0.05 part, phenoxyethanol 0.4 part, methyl hydroxybenzoate 0.2 part and 0.05 part, essence
Surplus is supplied with deionized water.
Have anti-acne trace and an essence for suppression acne growth function, every 100 weight portion essences comprise the molten phase component of following oil and water-dissolving phase component:
The molten phase component of oil: comprise as the component A in claim 1 3.0 parts, also comprise hydrolecithin 0.5 part, 0.1 part, Phosphoric acid monohexadecyl ester potassium, tea oil 1 part, Vitamin E acetate 0.1 part and polydimethylsiloxane 1 part,
Water-dissolving phase component: comprise as the B component in claim 1 9.0 parts, also comprise disodiumedetate 0.05 part, allantoin 0.2 part, glycerol 8 parts, butanediol 4 parts, sodium polyacrylate 0.5 part, xanthan gum 0.1 part, hyaluronate sodium 0.1 part, phenoxyethanol 0.4 part and methyl hydroxybenzoate 0.2 part
Surplus is supplied with deionized water.
Have anti-acne trace and a gel for suppression acne growth function, every 100 weight portion gels comprise the molten phase component of following oil and water-dissolving phase component:
The molten phase component of oil: comprise as the component A in claim 1 0.8 part, also comprise hydrolecithin 0.5 part, 0.1 part, Phosphoric acid monohexadecyl ester potassium, tea oil 1 part, Vitamin E acetate 0.1 part and polydimethylsiloxane 0.5 part,
Water-dissolving phase component: comprise as the B component in claim 1 2.2 parts, also comprise disodiumedetate 0.5 part, allantoin 0.2 part, glycerol 6 parts, butanediol 4 parts, sodium polyacrylate 0.6 part, hyaluronate sodium 0.05 part, phenoxyethanol 0.4 part and methyl hydroxybenzoate 0.2 part
Surplus is supplied with deionized water.
Plant and have anti-acne trace and the surfactant suppressing acne growth function, every 100 weight portion surfactant comprise the molten phase component of following oil and water-dissolving phase component:
The molten phase component of oil: comprise as the component A in claim 1 0.3 part, also comprise hydrolecithin 0.3 part, Vitamin E acetate 0.05 part and ring penta polydimethylsiloxane 0.5 part,
Water-dissolving phase component: comprise as the B component in claim 1 3.8 parts, also comprise disodiumedetate 0.05 part, allantoin 0.1 part, glycerol 5 parts, butanediol 4 parts, sodium polyacrylate 0.2 part, xanthan gum 0.2 part, hyaluronate sodium 0.05 part, phenoxyethanol 0.4 part and methyl hydroxybenzoate 0.2 part
Surplus is supplied with deionized water.
Have anti-acne trace and a facial film for suppression acne growth function, every 100 weight portion facial films comprise the molten phase component of following oil and water-dissolving phase component:
The molten phase component of oil: comprise as the component A in claim 1 0.4 part, also comprise cetearyl glucoside 3 parts, 0.5 part, Phosphoric acid monohexadecyl ester potassium, tea oil 4 parts, cetearyl alcohol 1.8 parts, Vitamin E acetate 0.1 part and polydimethylsiloxane 1 part,
Water-dissolving phase component: comprise as the B component in claim 1 0.85 part, also comprise disodiumedetate 0.05 part, allantoin 0.2 part, glycerol 6 parts, butanediol 4 parts, sodium polyacrylate 0.3 part, hydroxyethyl-cellulose 0.3 part, hyaluronate sodium 0.05 part, phenoxyethanol 0.4 part and methyl hydroxybenzoate 0.2 part
Surplus is supplied with deionized water.
Employing the present invention has following beneficial effect and is:
This combination derives from natural product: plant sterol is taken from that Vegetable oil lipoprotein, bisabolol extract from the quintessence oil of the trees of a kind of Candeia by name of Brazil, enoxolone stearic alcohol ester is taken from Radix Glycyrrhizae, phloretin takes from Pericarpium Mali pumilae and root of Fructus Mali pumilae (or synthetic), acetyl chitosan be taken from shrimp Eriocheir sinensis shell, heparin sodium is taken from pig small intestine, asiaticoside is taken from Herba Centellae, troxerutin derives from Flos Sophorae, the content of often kind of composition is more than 95%.
Prepare the active component of cosmetic composition of the present invention, there is following effect and feature:
Plant sterol (phytosterolorplantsterol) is a kind of active component in plant, extensively be present in each vegetable oil, nut, plant seed, vegetable and fruit, therefore, people just can obtain supplementing of plant sterol from daily meals, and it is a kind of important natural Exploitation of Sterol Resources.The plant sterol level of the usual meals of people is about 200 ~ 400mg/g, and the food of main supply has vegetable oil, margarine, vegetables and fruits, in vegetable oil, the highest with Testa oryzae oil content of phytosterol.Plant sterol is sterid, and its chemical constitution and biological function are similar to cholesterol, and both are only side chain at difference part, can be used for the reduction of body inner cholesterol.In addition, plant sterol also has anticancer, the function such as antiinflammatory, antioxidation, has been widely used in the industries such as food, pharmacy, health product.In recent years, by the development to composition of food scientific analysis physiological effect research relevant to plant sterol, particularly deepen constantly plant sterol health care understanding, plant sterol is researched and developed and gradually becomes focus, functional plants sterol food industries is also fast-developing.
Plant sterol has stronger antiinflammatory action to human body, has the effects such as the biochemistry synthesis that human body can be suppressed the absorption of cholesterol, the katabolism promoting cholesterol, suppression cholesterol.For the heart disease of prophylactic treatment coronary atherosclerosis class, there is obvious curative effect to treatment ulcer, Skin Squamous Cell Carcinoma, cervical cancer plant sterol etc.; Can wound healing be promoted, make hypertrophy, strengthen capillary circulation; Also can be used as the inhibitor that cholelithiasis is formed.Plant sterol or important steroid drugs and vitamin D
3raw materials for production.Plant sterol has very high permeability to skin, can keep skin surface moisture content, promotes skin metabolism, suppresses scytitis, can anti-sunburn, skin aging, also has effect of hair growth promoting, hair care.
α-bisabolol (Vanillomopsiserythropapa) is a kind of natural component extracted from the quintessence oil of Brazilian trees Candeia.Fractional distillation is out from quintessence oil for natural α-bisabolol: fractional distillation process according to the boiling point of different component from liquid mixture by component separating out.Containing (-) α-bisabolol isomer being no less than 95% in final products, usual content is 98%.Research shows to only have (-) α-bisabolol isomer to have activity.Bisabolol have unique antiinflammatory, anticorrosion, releive, antiinflammatory, antifungal, antibacterial activity, be specially adapted to the nursing of sensitivity skin.
The bisabolol of natural origin: CANDEIA tree is a kind of tropical shrub belonging to Compositae, is grown on southeast Brazil and midwestern Cerrado thick forest and thick grass area.The trunk of this tree is white, hard, interior resinous.Leaves and lace fragrance, and there is medical value.Quintessence oil is from wooden middle extraction.Be sesquiterpene structure (Fig.3) in α-bisabolol, this structure is found by Isaacetal.This be a kind of from natural material fractional distillation out there is optical activity, monocycle, undersaturated sesquiterpene alcohols.IUPAC title: (2S)-6-methyl-2-((1S)-4-methyl-3-cyclohexenyl group)-5-heptene-2-alcohol.
Anti-inflammatory activity: in inflammation generating process, mononuclear cell leaves blood and enters in the tissue that inflammation occurs as the part of Premeabilisation of cells.Inflammation nidus endothelial cell tissue can by molecular adhesion to mononuclear cell, and then they enter in tissue along inflammatory signals through endothelium.In the metabolite of arachidonic acid lamination, as leukotriene, prostaglandin and oxygen-derived free radicals play very important role.
α-bisabolol mechanism of action: the effect of α-bisabolol is by suppressing 5-lipoxygenase and cyclooxygenase, thus suppresses the generation of leukotriene and prostaglandin.
Pharmacology:
Janku and Zita determines bisabolol and has the affine performance suppressing various inflammation and skin.
Investigation afterwards shows its important results suppressing various inflammation to grow in the mode of data statistics, and test is Guinea piglets and mice is object, studies the edema experiment about formalin and protein.
Other experimental model:
1, the struvite of chondrus ocellatus Holmes edema is tested with it mouse
2, the arthritis with mouse is had to the effect of adjunctive therapy
3, Oleum Tiglii edema is tested with it mouse
4, on Guinea piglets, ultraviolet erythema is tested
In experiments all above, bisabolol all has obvious antiinflammatory, the effect of anti-inflammatory and against erythema.
The stearic alcohol ester of enoxolone is that enoxolone and stearyl alcohol are formed by esterification, compared with enoxolone, due to the molecular structure importing oil loving higher alkane in molecule, its dissolubility in oils and fats is significantly improved, can mix with multiple oils and fats and higher alcohol, compatibility is good: fusing point is low, and vapour pressure is high.There is antibacterial, antitumor and the effect of adrenocortical hormone sample, can be made into antiinflammatory antiallergic preparation, be used for the treatment of rheumatic arthritis, asthma, anaphylaxis and occupational dermatitis, diseases of eye, ear, nose and throat section inflammation and ulcer etc.Enoxolone is classical anti-inflammatory drug, be applied to the immunologic function of scalable skin in cosmetics, strengthen the resistance against diseases of skin, diminish inflammation, Polyglucan, cleaning skin, cosmetics and other extraneous factor can also be removed to the toxic and side effects of skin simultaneously.It can also the activation of effective restraint of tyrosinase, stops melanic generation, has white-skinned face function enoxolone Recent Progresses In The Development.
The stearic alcohol ester antiinflammatory action of enoxolone: Anderso and Tillman notices that the stearic alcohol ester of enoxolone is structurally similar with hydrocortisone the earliest, just it in various treating for skin disease, by many clinical trials, confirm the antiinflammatory effectiveness of the stearic alcohol ester of enoxolone.Start thus, vast medical circle has carried out a series of pharmacological research, finds manyly in this analog derivative all to have anti-inflammatory activity.Zakirov studies discovery: the aseptic arthritis of 3-amino-11-deoxy-glycyrrhetinic acid to all kinds of animal shows obvious anti-inflammatory activity.Toyoshima etc. prepare 11-deoxy-glycyrrhetinic acid maleate and salt thereof, and as antiinflammatory, also as antiulcer agent and immunomodulator, oral or topical therapeutic, all obtains good therapeutic effect.
The stearic alcohol ester antiulcer action of enoxolone: nineteen forty-six Revers has reported the antiulcer action of Radix Glycyrrhizae the earliest.Since then, Europe advances the research of this respect greatly, and throws oneself into and prepared the test of new drug by the stearic alcohol ester of enoxolone.Synthesize Castraausil salt, and find its healing effect to gastric ulcer.The Demande research of France in 1972 finds that 3-acetyl group-18-enoxolone and aluminum salt thereof are used for the treatment of duodenal ulcer, gastric ulcer, and curative effect is obvious.In addition, 11-deoxy-glycyrrhetinic acid amide, 3-oxy-acetyl enoxolone amide etc. are also very noticeable to the therapeutic effect of Peptic Ulcers.
Enoxolone antitumor proliferative activity: the researchs such as the Takizawa of Japan in 1985 find: the hypertrophy of enoxolone to muroid skin tumour has suppression to use.Nishino and Hoyoku etc. have carried out extensive research to the Enoxolone derivative of dependency structure, find 18-oleanane-12-alkene-3,23,28-triol has the tumor proliferative effect that the suppression stronger than enoxolone is caused by virus.
Phloretin is a kind of new type natural skin-whitening agents abroad recently researching and developing out, is mainly distributed in peel and the root bark of the rich fruit such as Fructus Mali pumilae, pears.The excessive secretion of sebaceous gland can also be suppressed, be used for the treatment of the vigorous type acne of secretion; Energy check melanin cytoactive, has effect to various skin splash; Can promote absorbing of other functional factor in formula, be one transdermal penetration enhancer safely and effectively; The weight 4-5 of energy absorption water doubly own, can double as wetting agent in formula; It also has very strong anti-oxidation function simultaneously, can remove the free radical in skin.Compare with kojic acid with similar natural component arbutin, the inhibitory action of phloretin to tryrosinase of comparable sodium is better than them, and when itself and arbutin and/or kojic acid carry out composite, greatly can improve the suppression ratio of product to tryrosinase, make suppression ratio reach 100%.
Phloretin, arbutin and kojic acid being compared as follows tyrosinase inhibitory action:
Concentration when the maximum tyrosinase inhibition rate of table one, phloretin, arbutin and kojic acid and 50% suppression ratio
| Classification | Maximum tyrosinase inhibition rate concentration (ICmax) | 50% suppression ratio concentration (IC50) |
| Phloretin | 0.3％ | 0.05％ |
| Arbutin | 1.4％ | 0.81％ |
| Kojic acid | 0.24％ | 0.038％ |
The phloretin of table two, various concentration, arbutin and kojic acid are to the suppression ratio of tryrosinase
Table three, phloretin and arbutin compatibility are to the suppression ratio of tryrosinase
| Concentration % | Suppression ratio % |
| Phloretin 0.06%+ arbutin 0.26% | 100.0 |
| Phloretin 0.12%+ arbutin 0.19% | 100.0 |
| Phloretin 0.17%+ arbutin 0.12% | 98.52 |
| Phloretin 0.23%+ arbutin 0.06% | 89.1 |
Table four, phloretin and kojic acid compatibility are to the suppression ratio of tryrosinase
| Concentration % | Suppression ratio % |
| Phloretin 0.06%+ kojic acid 0.25% | 85.5 |
| Phloretin 0.12%+ kojic acid 0.18% | 100.0 |
| Phloretin 0.18%+ kojic acid 0.12% | 100.0 |
| Phloretin 0.24%+ kojic acid 0.06% | 98.6 |
Table five, quality standard
| Inspection item | Unit | Standard specifies | Method |
| Outward appearance | Off-white color crystalline powder | Ocular estimate | |
| Moisture | ％ | ≤2.0 | Oven method |
| Fusing point | ℃ | 257-259℃ | Melting point apparatus method |
| Content | ％ | ≥98 | HPLC method |
| Total number of bacteria | Individual/gram | ＜500 | Dilution-plate method |
| Content of beary metal | ppm | ＜20 | Absorption spectrometry |
The function of phloretin:
1, the U.S. agent of novel, efficient, safe skin.Better than arbutin to the suppression ratio of tryrosinase, being equal to kojic acid, but not having the side effect of kojic acid, is one freckle removing and whitening agent very safely and effectively.
2, very strong moisture-keeping function, can the weight 4-5 of absorption moisture doubly own.
3, be one transdermal penetration enhancer very safely and effectively, absorbing of other functional factor in formula can be promoted, make it give play to better effect.
4, there is very strong anti-oxidation function, the free radical in skin can be removed.
5, the excessive secretion of sebaceous gland can be suppressed, the vigorous type acne for the treatment of secretion.
Acetyl chitosan, also known as N-Acetyl-D-glucosamine, natural N-Acetyl-D-glucosamine (oligosaccharide NAG) for shrimp and crab shells is through deproteinize and after going mineral process, then is made with special natural ferment hydrolysis.Experiment find to have increase skin hyaluronic acid containing content, slow down arthralgia, improve diabetes and hepatitis symptom and promote effect of immunocompetence.NAG is a kind of efficient moisture-retention composition.It is by promoting that the hydration function of skin reaches whitening effect.In addition, NAG also has the effect of restraint of tyrosinase activity, and the melanin in melanocyte can be suppressed to generate.In addition, NAG can also regulate the adhesion of corneocyte, promote that horny layer is peeled off, and promotes the new city metabolism of skin, makes skin seem healthy, pale, penetrating.
Heparin sodium, heparin sodium is mucopolysaccharide sulfuric acid ester anticoagulant.Heparin sodium is the sodium salt of the CSSO3 extracted in the intestinal mucosa by pig or cattle, belongs to mucopolysaccharide material.With powerful negative charge, there is the effect strengthening antithrombin Ⅲ deactivation serine protease, thus stop the formation of thrombin, and have multiple anticoagulations such as stoping platelet aggregation.Current heparin is in the world the most effectively and the maximum anticoagulation medicine of quantity, is mainly used in cardiovascular and cerebrovascular disease and hemodialysis, and wherein, it is unique effective specific medicament in hemodialysis.Clinical practice and research display, heparin, except having blood coagulation resisting function, also has other multiple biological activity and clinical applications, comprises effect for reducing blood fat, anti-middle film smooth muscle cell (SMC) hypertrophy, promotes the effects such as fibrinolysis.In addition, Low molecular heparin is the antithrombotic medicine of a large class be processed into further as raw material by heparin crude drug, there is clinical medicine purposes more widely, become the choice drug of disease such as treatment Acute Venous thrombosis and acute coronary artery syndrome (angina pectoris, myocardial infarction) etc.
Asiaticoside, asiaticoside is also known as Asiaticoside, faint yellow to fallow powder; Odorless, bitter in the mouth, slightly have draw moist.There is promotion Wound Healing.Be used for the treatment of wound, operation wound, burn, keloid and scleroderma.Asiaticoside has the function strengthening reticuloendothelial system, excites blood capillary to regenerate, improves blood circulation, activates epithelial tissue, promotes that normal granulation tissue is formed, accelerates wound repair.Experimental data shows that LPS obviously can induce propagation and the inflammatory factor release of In vitro culture microglia.Compare with LPS group, asiaticoside has remarkable inhibitory action to the microglia propagation that LPS induces, and has dose dependent, and the IC50 of asiaticoside process microglia 48h is 10.97nmol/L.Asiaticoside makes the release of microglia TNF-α and IL-6 significantly reduce (P < 0.05) simultaneously; Asiaticoside makes the G2 phase cell of microglia and apoptosis rate increase, and reduces the expression of microglia TLR4 and NF-κ B.Asiaticoside to the propagation of the microglia that LPS stimulates and the generation of inflammatory factor inhibited, its mechanism of action may be expressed with suppression TLR-4 and NF-κ B, change cell cycle and cell death inducing is relevant.
Troxerutin, different name: hydroxyethyl rutin, troxerutin, troxerutin, extract rutin from Flos Sophorae, again through semi-synthetic chromocor compound that hydroxyethylation is made, have and suppress erythrocyte and platelet aggregation effect, prevent thrombosis, the content of oxygen in blood can be increased simultaneously, improve microcirculation, promote that new vascular generation is to promote Doppler flow mapping.Its Human Umbilical Vein Endothelial Cells has protective effect; to ease up the blood vessel injury that kassinin kinin causes to medmain, increase the resistance of blood capillary, reduce the permeability of blood capillary; have the effect of edema preventing from causing because vascular permeability raises, and have resistance to radioactive injuries, anti-inflammatory,
Described compositions adds emulsifying agent, antiseptic, thickening agent and wetting agent and can be made into cream, emulsion, essence, cosmetic water and gel,
Described emulsifying agent comprises: one or more in cetearyl glucoside, Phosphoric acid monohexadecyl ester potassium, hydrolecithin, glyceryl stearate (SE), Cremophor RH40 ester,
Described antiseptic comprises: one or more in phenoxyethanol, methyl hydroxybenzoate, ethyl hydroxybenzoate, propyl hydroxybenzoate, Methylisothiazolinone, diazolidinyl urea, iodine propilolic alcohol butyl mephenesin Carbamate,
Described thickening agent comprises: one or more in carbomer, xanthan gum, hydroxyethyl-cellulose, carrageenan, 2-(Acryloyloxy)ethanol/sodium acryloyldimethyl taurate copolymers,
Described wetting agent comprises: one or more in glycerol, propylene glycol, butanediol, sorbitol, erithritol, xylitol.
Detailed description of the invention
Be described principle of the present invention and feature below in conjunction with specific embodiment, example, only for explaining the present invention, is not intended to limit scope of the present invention.
Embodiment one
There is anti-acne trace and a compositions for suppression acne growth function, comprise component A and B component,
Described component A comprises the raw material of following weight portion: the stearic alcohol ester 0.5g of plant sterol 1g, bisabolol 1g and enoxolone;
Described B component comprises the raw material of following weight g: phloretin 1g, acetyl chitosan 5g, heparin sodium 1g, asiaticoside 1g and troxerutin 2g;
Component A and B component weight ratio are 2.5:10.
Embodiment two
There is anti-acne trace and a compositions for suppression acne growth function, comprise component A and B component,
Described component A comprises the raw material of following weight portion: the stearic alcohol ester 0.5g of plant sterol 0.2g, bisabolol 0.8g and enoxolone;
Described B component comprises the raw material of following weight g: phloretin 1g, acetyl chitosan 4g, heparin sodium 0.5g, asiaticoside 1g and troxerutin 2g;
Component A and B component weight ratio are 1.5:8.5.
Embodiment three
There is anti-acne trace and a compositions for suppression acne growth function, comprise component A and B component,
Described component A comprises the raw material of following weight portion: the stearic alcohol ester 0.5g of plant sterol 0.5g, bisabolol 0.5g and enoxolone;
Described B component comprises the raw material of following weight portion: phloretin 0.5g, acetyl chitosan 3g, heparin sodium 0.5g, asiaticoside 0.5g and troxerutin 1.5g;
Component A and B component weight ratio are 1.5:6.
Embodiment four
Have anti-acne trace and a cream for suppression acne growth function, every 100g cream comprises following component:
The molten phase component of oil:
Water-dissolving phase component:
Wherein component A comprises plant sterol 0.5g, bisabolol 1g, the stearic alcohol ester 0.5g of enoxolone; B component comprises phloretin 1g, acetyl chitosan 3g, heparin sodium 1g, asiaticoside 1g and troxerutin 1g.
A kind of have anti-acne trace and suppress the cream preparation method of acne growth function as follows:
Oil phase, aqueous phase are heated to 80 DEG C respectively, and two-phase mixtures is rear all prime numbers minute evenly, and stir cooling, 45 DEG C add essence, stir, and make fine and smooth mastic for 35 DEG C; Mastic to be weighed bottling.
Embodiment five
Have anti-acne trace and an emulsion for suppression acne growth function, every 100g emulsion comprises following component:
The molten phase component of oil:
Water-dissolving phase component:
Wherein component A comprises plant sterol 0.5g, bisabolol 0.5g, the stearic alcohol ester 0.5g of enoxolone; B component comprises phloretin 0.5g, acetyl chitosan 2g, heparin sodium 0.3g, asiaticoside 0.2g and troxerutin 1g.
A kind of have anti-acne trace and suppress the preparation method of the emulsion of acne growth function identical with embodiment four.
Embodiment six
Have anti-acne trace and an essence for suppression acne growth function, every 100g essence comprises following component:
The molten phase component of oil:
Water-dissolving phase component:
Wherein component A comprises the stearic alcohol ester 1.0g of plant sterol 1.0g, bisabolol 1.0g and enoxolone; B component comprises phloretin 1g, acetyl chitosan 4g, heparin sodium 1g, asiaticoside 1g and troxerutin 2g.
A kind of have anti-acne trace and suppress the preparation method of the essence of acne growth function as follows:
Oil phase, aqueous phase are heated to 80 DEG C respectively, and two-phase mixtures is rear all prime numbers minute evenly, stir cooling, stir, make fine and smooth mastic for 35 DEG C; Mastic to be weighed bottling.
Embodiment seven
Have anti-acne trace and a gel for suppression acne growth function, every 100g gel comprises following component:
The molten phase component of oil:
Water-dissolving phase component:
Wherein component A comprises the stearic alcohol ester 0.2g of plant sterol 0.3g, bisabolol 0.3g and enoxolone; B component comprises phloretin 0.2g, acetyl chitosan 1.5g, heparin sodium 0.1g, asiaticoside 0.2g and troxerutin 0.2g.
A kind of have anti-acne trace and suppress the preparation method of the essence of acne growth function identical with embodiment six.
Embodiment eight
Have anti-acne trace and a surfactant for suppression acne growth function, every 100g surfactant comprises following component:
The molten phase component of oil:
Water-dissolving phase component:
Wherein component A comprises the stearic alcohol ester 0.1g of plant sterol 0.1g, bisabolol 0.1g and enoxolone; B component comprises phloretin 0.1g, acetyl chitosan 3.0g, heparin sodium 0.1g, asiaticoside 0.1g and troxerutin 0.5g.
A kind of have anti-acne trace and suppress the preparation method of the surfactant of acne growth function identical with embodiment six.
Embodiment nine
Have anti-acne trace and a facial film for suppression acne growth function, every 100 weight portion facial films comprise following component:
The molten phase component of oil:
Water-dissolving phase component:
Wherein component A comprises the stearic alcohol ester 0.1g of plant sterol 0.1g, bisabolol 0.1g and enoxolone; B component comprises phloretin 0.1g, acetyl chitosan 0.5g, heparin sodium 0.05g and asiaticoside 0.1g.
A kind of have anti-acne trace and suppress the preparation method of the facial film of acne growth function identical with embodiment six.
Both effectiveness test:
One, normal individual trial evaluation experimental
1, experimental technique
Embodiment one carries out normal individual trial evaluation.Choose acne and cure rear patient 16, the age, men and women half and half at 18 ~ 25 years old.Wherein male IV degree heavily suffers from 3, women IV degree heavily suffers from 1.Carry out controlled trial respectively, left side does not use any product, right side uses this routine sample, take pictures before using and keep on file, use two to three times after clean of every day, continue surrounding on probation, use first week, second week, after the 3rd week and 4th week, observe the pockmark apparent condition of left face and right face respectively, after surrounding with use before photo comparison, observe the emerging acne of left and right face simultaneously and generate situation.
Evaluate sample colourity, color print area, wound surface flatness and newborn acne quantity in use procedure, wherein best result is 5, is minimumly divided into 1.
2, experimental result
Evaluation table on probation is filled according to sensory evaluation.Collect half face experiment evaluation table on probation, statistical result sees the following form:
Normal individual trial evaluation result meansigma methods:
From upper table result, the result of human body half face test evaluation clearly can contrast effect difference of this routine sample and blank sample, the improvement aspect successful of colourity, color print area, wound surface flatness and newborn acne quantity, show, containing the present invention, there is anti-acne trace and suppress the anti-acne trace frost of the cosmetic composition of acne systematic functions, there is the red pox print of good elimination, subtract light black pox print, repair pox scar and suppress the function of the generation of new acne.
Wherein component A and B component ratio change to carry out testing and also can obtain good experimental result.
Two, normal individual trial evaluation experimental
1, experimental technique
Embodiment two carries out normal individual trial evaluation.Choose acne and cure rear patient 16, the age, men and women half and half at 18 ~ 25 years old.Wherein male IV degree heavily suffers from 3, women IV degree heavily suffers from 1.Carry out controlled trial respectively, left side does not use any product, right side uses this routine sample, take pictures before using and keep on file, use two to three times after clean of every day, continue surrounding on probation, use first week, second week, after the 3rd week and 4th week, observe the pockmark apparent condition of left face and right face respectively, after surrounding with use before photo comparison, observe the emerging acne of left and right face simultaneously and generate situation.
Evaluate sample colourity, color print area, wound surface flatness and newborn acne quantity in use procedure, wherein best result is 5, is minimumly divided into 1.
2, experimental result
Evaluation table on probation is filled according to sensory evaluation.Collect half face experiment evaluation table on probation, statistical result sees the following form:
Normal individual trial evaluation result meansigma methods:
From upper table result, the result of human body half face test evaluation clearly can contrast effect difference of this routine sample and blank sample, the improvement aspect successful of colourity, color print area, wound surface flatness and newborn acne quantity, show, containing the present invention, there is anti-acne trace and suppress the anti-acne trace frost of the cosmetic composition of acne systematic functions, there is the red pox print of good elimination, subtract light black pox print, repair pox scar and suppress the function of the generation of new acne.
Wherein component A and B component ratio change to carry out testing and also can obtain good experimental result.
The foregoing is only preferred embodiment of the present invention, not in order to limit the present invention, within the spirit and principles in the present invention all, any amendment done, equivalent replacement, improvement etc., all should be included within protection scope of the present invention.
Claims (10)
1. there is anti-acne trace and a compositions for suppression acne growth function, it is characterized in that, comprise component A and B component,
Described component A comprises the raw material of following weight portion: the stearic alcohol ester 0.1 ~ 1 part of plant sterol 0.1 ~ 1 part, bisabolol 0.1 ~ 2 part and enoxolone;
Described B component comprises the raw material of following weight portion: phloretin 0.1 ~ 1 part, acetyl chitosan 0.5 ~ 5 part, heparin sodium 0.05 ~ 1 part, asiaticoside 0.1 ~ 1 part and troxerutin 0.1 ~ 2 part;
Described component A and described B component weight ratio are 0.3 ~ 3:0.85 ~ 10.
2. according to claim 1 a kind ofly have anti-acne trace and suppress the compositions of acne growths function, it is characterized in that, comprise component A and B component,
Described component A comprises the raw material of following weight portion: the stearic alcohol ester 0.1 ~ 0.5 part of plant sterol 0.2 ~ 1 part, bisabolol 0.1 ~ 1 part and enoxolone;
Described B component comprises the raw material of following weight portion: phloretin 0.1 ~ 1 part, acetyl chitosan 0.5 ~ 4 part, heparin sodium 0.05 ~ 0.5 part, asiaticoside 0.1 ~ 1 part and troxerutin 0.1 ~ 20 part;
Described component A and described B component weight ratio are 0.4 ~ 2.5:0.85 ~ 8.5.
3. according to claim 1 a kind ofly have anti-acne trace and suppress the compositions of acne growths function, it is characterized in that, comprise component A and B component,
Described component A comprises the raw material of following weight portion: the stearic alcohol ester 0.5 part of plant sterol 0.5 part, bisabolol 0.5 part and enoxolone;
Described B component comprises the raw material of following weight portion: phloretin 0.5 part, acetyl chitosan 3 parts, heparin sodium 0.5 part, asiaticoside 0.5 part and troxerutin 1.5 parts;
Described component A and described B component weight ratio are 1.5:6.
4. described in an any one of claims 1 to 3, there is anti-acne trace and the application of compositions on skin nursing products of suppression acne growth function.
5. have anti-acne trace and a cream for suppression acne growth function, it is characterized in that, every 100 weight portion cream comprise the molten phase component of following oil and water-dissolving phase component:
The molten phase component of described oil comprises the material of following weight portion: have anti-acne trace described in any one of claims 1 to 3 and suppress the component A 2.0 parts in the compositions of acne growth function and cetearyl glucoside 3 parts, 0.5 part, Phosphoric acid monohexadecyl ester potassium, tea oil 4 parts, cetearyl alcohol 1.8 parts, Vitamin E acetate 0.1 part and polydimethylsiloxane 1 part
Described water-dissolving phase component comprises the material of following weight portion: have anti-acne trace described in any one of claims 1 to 3 and suppress the B component 7.0 parts in the compositions of acne growth function and disodiumedetate 0.05 part, allantoin 0.2 part, glycerol 6 parts, butanediol 4 parts, sodium polyacrylate 0.3 part, xanthan gum 0.1 part, hyaluronate sodium 0.05 part, phenoxyethanol 0.4 part, methyl hydroxybenzoate 0.2 part and 0.05 part, essence
Surplus is supplied with deionized water.
6. have anti-acne trace and an emulsion for suppression acne growth function, it is characterized in that, every 100 weight portion emulsions comprise the molten phase component of following oil and water-dissolving phase component:
The molten phase component of described oil: there is described in any one of claims 1 to 3 anti-acne trace and suppress the component A 1.5 parts in the compositions of acne growth function and cetearyl glucoside 1.5 parts, 0.3 part, Phosphoric acid monohexadecyl ester potassium, tea oil 2 parts, cetearyl alcohol 0.8 part, Vitamin E acetate 0.1 part and polydimethylsiloxane 1 part
Described water-dissolving phase component: there is described in any one of claims 1 to 3 anti-acne trace and suppress the B component 4.0 parts in the compositions of acne growth function and disodiumedetate 0.05 part, allantoin 0.2 part, glycerol 6 parts, butanediol 4 parts, sodium polyacrylate 0.2 part, xanthan gum 0.1 part, hyaluronate sodium 0.05 part, phenoxyethanol 0.4 part, methyl hydroxybenzoate 0.2 part and 0.05 part, essence
Surplus is supplied with deionized water.
7. have anti-acne trace and an essence for suppression acne growth function, it is characterized in that, every 100 weight portion essences comprise the molten phase component of following oil and water-dissolving phase component:
The molten phase component of described oil: there is described in any one of claims 1 to 3 anti-acne trace and suppress the component A 3.0 parts in the compositions of acne growth function and hydrolecithin 0.5 part, 0.1 part, Phosphoric acid monohexadecyl ester potassium, tea oil 1 part, Vitamin E acetate 0.1 part and polydimethylsiloxane 1 part
Described water-dissolving phase component: there is described in any one of claims 1 to 3 anti-acne trace and suppress the B component 9.0 parts in the compositions of acne growth function and disodiumedetate 0.05 part, allantoin 0.2 part, glycerol 8 parts, butanediol 4 parts, sodium polyacrylate 0.5 part, xanthan gum 0.1 part, hyaluronate sodium 0.1 part, phenoxyethanol 0.4 part and methyl hydroxybenzoate 0.2 part
Surplus is supplied with deionized water.
8. have anti-acne trace and a gel for suppression acne growth function, it is characterized in that, every 100 weight portion gels comprise the molten phase component of following oil and water-dissolving phase component:
The molten phase component of described oil: there is described in any one of claims 1 to 3 anti-acne trace and suppress the component A 0.8 part in the compositions of acne growth function and hydrolecithin 0.5 part, 0.1 part, Phosphoric acid monohexadecyl ester potassium, tea oil 1 part, Vitamin E acetate 0.1 part and polydimethylsiloxane 0.5 part
Described water-dissolving phase component: there is described in any one of claims 1 to 3 anti-acne trace and suppress the B component 2.2 parts in the compositions of acne growth function and disodiumedetate 0.5 part, allantoin 0.2 part, glycerol 6 parts, butanediol 4 parts, sodium polyacrylate 0.6 part, hyaluronate sodium 0.05 part, phenoxyethanol 0.4 part and methyl hydroxybenzoate 0.2 part
Surplus is supplied with deionized water.
9. kind have anti-acne trace and suppress the surfactant of acne growth function, it is characterized in that, every 100 weight portion surfactant comprise the molten phase component of following oil and water-dissolving phase component:
The molten phase component of described oil: there is described in any one of claims 1 to 3 anti-acne trace and suppress the component A 0.3 part in the compositions of acne growth function and hydrolecithin 0.3 part, Vitamin E acetate 0.05 part and ring penta polydimethylsiloxane 0.5 part,
Described water-dissolving phase component: there is described in any one of claims 1 to 3 anti-acne trace and suppress the B component 3.8 parts in the compositions of acne growth function and disodiumedetate 0.05 part, allantoin 0.1 part, glycerol 5 parts, butanediol 4 parts, sodium polyacrylate 0.2 part, xanthan gum 0.2 part, hyaluronate sodium 0.05 part, phenoxyethanol 0.4 part and methyl hydroxybenzoate 0.2 part
Surplus is supplied with deionized water.
10. have anti-acne trace and a facial film for suppression acne growth function, it is characterized in that, every 100 weight portion facial films comprise the molten phase component of following oil and water-dissolving phase component:
The molten phase component of described oil: there is described in any one of claims 1 to 3 anti-acne trace and suppress the component A 0.4 part in the compositions of acne growth function and cetearyl glucoside 3 parts, 0.5 part, Phosphoric acid monohexadecyl ester potassium, tea oil 4 parts, cetearyl alcohol 1.8 parts, Vitamin E acetate 0.1 part and polydimethylsiloxane 1 part
Described water-dissolving phase component: there is described in any one of claims 1 to 3 anti-acne trace and suppress the B component 0.85 part in the compositions of acne growth function and disodiumedetate 0.05 part, allantoin 0.2 part, glycerol 6 parts, butanediol 4 parts, sodium polyacrylate 0.3 part, hydroxyethyl-cellulose 0.3 part, hyaluronate sodium 0.05 part, phenoxyethanol 0.4 part and methyl hydroxybenzoate 0.2 part
Surplus is supplied with deionized water.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510873881.2A CN105380830B (en) | 2015-12-02 | 2015-12-02 | A kind of composition and its application with anti-acne trace and suppression acne systematic function |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510873881.2A CN105380830B (en) | 2015-12-02 | 2015-12-02 | A kind of composition and its application with anti-acne trace and suppression acne systematic function |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105380830A true CN105380830A (en) | 2016-03-09 |
| CN105380830B CN105380830B (en) | 2017-11-21 |
Family
ID=55414013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510873881.2A Active CN105380830B (en) | 2015-12-02 | 2015-12-02 | A kind of composition and its application with anti-acne trace and suppression acne systematic function |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105380830B (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107184410A (en) * | 2017-04-28 | 2017-09-22 | 广州瑞誉化工科技有限公司 | A kind of skin cream with steroid dependent dermatitis repair function |
| CN108175727A (en) * | 2017-12-28 | 2018-06-19 | 广州蜜妆生物科技有限公司 | A kind of anti-acne print Face-protecting mask patch and preparation method thereof |
| CN109568231A (en) * | 2018-12-30 | 2019-04-05 | 广州瑞誉化工科技有限公司 | It is a kind of can Red blood streak dispelling skin composition and its preparation method and application |
| CN110063925A (en) * | 2019-03-19 | 2019-07-30 | 广东医科大学 | A kind of acne-removing composition and preparation method thereof |
| CN110302087A (en) * | 2019-08-16 | 2019-10-08 | 广州立白企业集团有限公司 | Maintenance composition, the composite skin care product using and containing the maintenance composition |
| CN114028271A (en) * | 2021-11-26 | 2022-02-11 | 西安德诺海思医疗科技有限公司 | Oil-control acne-removing composition and preparation method thereof |
| CN116869886A (en) * | 2023-07-27 | 2023-10-13 | 广州市精锐生物研究有限公司 | Acne-removing composition, and preparation method and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030082116A1 (en) * | 2001-09-28 | 2003-05-01 | Closure Medical Corporation | Adhesive compositions containing dual function stabilizers and active agents |
| CN1931269A (en) * | 2006-10-13 | 2007-03-21 | 深圳市生物谷科技有限公司 | Rutin containing medicine composition |
| CN103976907A (en) * | 2014-05-29 | 2014-08-13 | 暨南大学 | Cosmetic comprising composition with slow anti-allergic action as well as preparation method and application thereof |
| CN104997711A (en) * | 2015-07-20 | 2015-10-28 | 陈巨根 | Scar dispelling and speckle removing essential oil |
-
2015
- 2015-12-02 CN CN201510873881.2A patent/CN105380830B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030082116A1 (en) * | 2001-09-28 | 2003-05-01 | Closure Medical Corporation | Adhesive compositions containing dual function stabilizers and active agents |
| CN1931269A (en) * | 2006-10-13 | 2007-03-21 | 深圳市生物谷科技有限公司 | Rutin containing medicine composition |
| CN103976907A (en) * | 2014-05-29 | 2014-08-13 | 暨南大学 | Cosmetic comprising composition with slow anti-allergic action as well as preparation method and application thereof |
| CN104997711A (en) * | 2015-07-20 | 2015-10-28 | 陈巨根 | Scar dispelling and speckle removing essential oil |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107184410A (en) * | 2017-04-28 | 2017-09-22 | 广州瑞誉化工科技有限公司 | A kind of skin cream with steroid dependent dermatitis repair function |
| CN108175727A (en) * | 2017-12-28 | 2018-06-19 | 广州蜜妆生物科技有限公司 | A kind of anti-acne print Face-protecting mask patch and preparation method thereof |
| CN109568231A (en) * | 2018-12-30 | 2019-04-05 | 广州瑞誉化工科技有限公司 | It is a kind of can Red blood streak dispelling skin composition and its preparation method and application |
| CN110063925A (en) * | 2019-03-19 | 2019-07-30 | 广东医科大学 | A kind of acne-removing composition and preparation method thereof |
| CN110302087A (en) * | 2019-08-16 | 2019-10-08 | 广州立白企业集团有限公司 | Maintenance composition, the composite skin care product using and containing the maintenance composition |
| CN114028271A (en) * | 2021-11-26 | 2022-02-11 | 西安德诺海思医疗科技有限公司 | Oil-control acne-removing composition and preparation method thereof |
| CN114028271B (en) * | 2021-11-26 | 2022-11-08 | 西安德诺海思医疗科技有限公司 | Oil-control acne-removing composition and preparation method thereof |
| CN116869886A (en) * | 2023-07-27 | 2023-10-13 | 广州市精锐生物研究有限公司 | Acne-removing composition, and preparation method and application thereof |
| CN116869886B (en) * | 2023-07-27 | 2024-04-02 | 广州市精锐生物研究有限公司 | Acne-removing composition, and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105380830B (en) | 2017-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105380830B (en) | A kind of composition and its application with anti-acne trace and suppression acne systematic function | |
| CN103494747B (en) | Compound peony skin-caring essential oil and preparation method thereof | |
| KR101373636B1 (en) | Composition for improving condition of skin and scalp containing fermented extracts of herb mixture | |
| CN105395467B (en) | A kind of Chinese medicine composition, skin beautifying cosmetic and its application | |
| CN105434195B (en) | A kind of composition and its application with anti-acne and suppression pockmark systematic function | |
| KR102033089B1 (en) | Compositions for decreasing sebum, skin desquamation and skin suppression | |
| KR101064904B1 (en) | Cosmetic composition for improving acne comprising natural extracts | |
| JPWO2004085429A1 (en) | Composition for promoting type I collagen and / or elastin production | |
| KR101387308B1 (en) | Skin whitening composition by using of dendropanax morbifera ferment extract | |
| JP2010132629A (en) | External composition for skin | |
| JP2017193560A (en) | Sebum production-inhibiting composition comprising saururus chinensis extract | |
| CN102274141B (en) | Herba selaginellae revival moisturizing cream and preparation method thereof | |
| CN105213284A (en) | A kind of anti-acne moisturiser and preparation method thereof | |
| CN113694115A (en) | Application of Fuzhuan tea extract in preparation of skin conditioning product | |
| CN105997827A (en) | Compound camellia oil moisturizer and preparation method thereof | |
| TW201642849A (en) | Compositions including sesamin, methods of making and using the same in skin anti-aging and skin lightening applications | |
| JP2008184416A (en) | External preparation for skin, cell activation agent and antioxidation agent | |
| KR100769302B1 (en) | Skin topical composition containing herbal extract for treating and improving scar pruritus | |
| JP2020502172A (en) | Cosmetic composition containing Chinese herbal extract as active ingredient | |
| CN112266825A (en) | Compound essential oil, preparation method thereof and application of compound essential oil in whitening and anti-wrinkle cosmetics | |
| CN104398426A (en) | Mask for treating common acne | |
| CN115429738B (en) | Acne-removing, repairing and reviving essence and preparation method thereof | |
| KR101430636B1 (en) | Functional cosmetic composition comprising ginsenosides Rh2 and Rg3 | |
| CN108403485A (en) | Natural herb sunscreen | |
| KR20160036834A (en) | Skin external application composition comprising complex fermented extract of crude drug ingredients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20201224 Address after: No.6, 1st floor, unit 107, building 1, No.1, middle section of Tianfu Avenue, Chengdu high tech Zone, Chengdu, Sichuan 610213 Patentee after: Strawberry jam Technology Chengdu Co.,Ltd. Address before: 510000 706, building 6, Hongtai wisdom Valley, 21 Sicheng Road, Tianhe District, Guangzhou City, Guangdong Province Patentee before: GUANGZHOU DOUHU BIOTECHNOLOGY Co.,Ltd. Patentee before: Yin Chuanjiang Patentee before: Yang Min |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20240517 Address after: Room 323, No.1 Huaxu Street, Tianhe District, Guangzhou City, Guangdong Province, 510630 Patentee after: Amoer (Guangzhou) Biotechnology Co.,Ltd. Country or region after: China Address before: No.6, 1st floor, unit 107, building 1, No.1, middle section of Tianfu Avenue, Chengdu high tech Zone, Chengdu, Sichuan 610213 Patentee before: Strawberry jam Technology Chengdu Co.,Ltd. Country or region before: China |